Skip to content
Screener

Alumis Inc. ALMS Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Amgen logo
AmgenAMGN
16.7×-3.4×
Immunome logo
ImmunomeIMNM
4.2×+2.3×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
5×+3.9×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
2.2×+1.7×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.2×-0.2×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

market cap/total stockholders equity=4.9×

Based on the most recent quarter.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s price / book?
Alumis Inc. (ALMS) reported price / book of 4.9× in Q1 2026.
How has Alumis Inc.'s price / book changed year-over-year?
Alumis Inc.'s price / book increased by 149.0% year-over-year, from 2× to 4.9×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Alumis Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude